Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.480
-0.050 (-3.27%)
Oct 30, 2026, 4:00 PM EDT - Market closed
Actinium Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Actinium Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $4.00. The average 1-year stock price forecast is 170.27% higher than the current stock price, while the lowest is $3.00 (+102.70%) and the highest is $5.00 (+237.84%).
Price Target: $4.00 (+170.27%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Actinium Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JonesTrading | JonesTrading | Buy Reiterates $3 | Buy | Reiterates | $3 | +102.70% | Oct 21, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $4 | Buy | Reiterates | $4 | +170.27% | Oct 20, 2026 |
Financial Forecast
Revenue This Year
35.00M
from 90.00K
Increased by 38,788.89%
Revenue Next Year
n/a
from 35.00M
Decreased by -100.00%
EPS This Year
0.14
from -1.09
EPS Next Year
-0.53
from 0.14
EPS and Forward PE are based on non-GAAP adjusted numbers.